Teva Pharmaceutical Industries Ltd. $TEVA Stock Purchased by Migdal Insurance & Financial Holdings Ltd.

Key Points

• Migdal Insurance increased its Teva stake by 1.3%, purchasing 500,000 shares in the third quarter to hold 39.4 million shares, worth about $1.56 billion and representing 3.38% of Teva.
• Teva beat quarterly earnings expectations, reporting EPS of $0.86 versus the $0.72 consensus and revenue of $4.39 billion versus estimates of $4.23 billion; revenue was down 1.9% year over year.
• Analyst sentiment was broadly positive: Teva had a “Moderate Buy” consensus and a $48.15 average price target, with several firms raising targets, including Piper Sandler to $56.

Migdal Insurance & Financial Holdings Ltd. increased its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 1.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 39,422,212 shares of the company's stock after buying an additional 500,000 shares during the quarter. Teva Pharmaceutical Industries comprises 9.6% of Migdal Insurance & Financial Holdings Ltd.'s holdings, making the stock its largest position. Migdal Insurance & Financial Holdings Ltd. owned 3.38% of Teva Pharmaceutical Industries worth $1,561,120,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Parallel Advisors LLC grew its holdings in Teva Pharmaceutical Industries by 8.7% in the 3rd quarter. Parallel Advisors LLC now owns 4,626 shares of the company's stock valued at $183,000 after buying an additional 370 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its holdings in shares of Teva Pharmaceutical Industries by 7.1% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 7,311 shares of the company's stock worth $248,000 after acquiring an additional 483 shares during the period. First Trust Advisors LP raised its holdings in shares of Teva Pharmaceutical Industries by 5.9% during the 1st quarter. First Trust Advisors LP now owns 9,619 shares of the company's stock worth $290,000 after acquiring an additional 539 shares during the period. EverSource Wealth Advisors LLC raised its holdings in shares of Teva Pharmaceutical Industries by 64.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company's stock worth $50,000 after acquiring an additional 647 shares during the period. Finally, Victrix Investment Advisors boosted its position in shares of Teva Pharmaceutical Industries by 9.5% during the 2nd quarter. Victrix Investment Advisors now owns 7,850 shares of the company's stock valued at $266,000 after acquiring an additional 681 shares during the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Trading Up 2.0%

NYSE:TEVA traded up $0.87 on Friday, reaching $44.52. The company's stock had a trading volume of 7,562,490 shares, compared to its average volume of 6,968,955. Teva Pharmaceutical Industries Ltd. has a 12-month low of $24.01 and a 12-month high of $44.57. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 1.59. The firm has a market cap of $51.88 billion, a price-to-earnings ratio of 103.53, a price-to-earnings-growth ratio of 4.09 and a beta of 0.97. The stock has a 50 day moving average price of $40.16 and a 200 day moving average price of $35.07.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.72 by $0.14. The business had revenue of $4.39 billion for the quarter, compared to analyst estimates of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The company's quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.78 EPS. On average, equities analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.98 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TEVA has been the subject of a number of analyst reports. Piper Sandler upped their price objective on shares of Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the company an "overweight" rating in a report on Thursday. Oppenheimer lifted their target price on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the stock an "outperform" rating in a research note on Friday, October 9th. Weiss Ratings upgraded shares of Teva Pharmaceutical Industries from a "hold (c)" rating to a "hold (c+)" rating in a report on Wednesday, November 4th. UBS Group boosted their target price on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a "buy" rating in a report on Friday, September 4th. Finally, TD Cowen increased their price target on shares of Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the company a "buy" rating in a research note on Wednesday, November 4th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $48.15.

Key Headlines Impacting Teva Pharmaceutical Industries

Here are a few of the latest headlines about TEVA:

• Positive Sentiment: Piper Sandler raised its price target to $56 from $44 and maintained an Overweight rating, pointing to potential upside. HC Wainwright also issued a positive forecast for Teva’s FY2026 earnings, though the report provided no further details. Piper Sandler analyst rating HC Wainwright forecast
• Positive Sentiment: At its R&D Day, Teva outlined a target of $6–7 billion in innovative-medicines revenue by 2030 and highlighted potential first-in-class pipeline treatments, including for Tourette syndrome, celiac disease and intestinal scarring. These are longer-term opportunities, not guaranteed results. Teva R&D Day announcement
• Negative Sentiment: CEO Richard Francis sold 250,000 shares for about $10.56 million, reducing his direct ownership by 21.23%. EVP Richard Daniell also sold shares in two reported transactions—20,003 shares on Nov. 11 and 25,000 on Nov. 9—cutting his reported stake. Insider selling can weigh on sentiment, although it does not by itself establish the executives’ view of Teva’s prospects. CEO SEC filing EVP SEC filing

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 46,000 shares of the stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $41.93, for a total transaction of $1,928,780.00. Following the completion of the transaction, the insider owned 80,760 shares of the company's stock, valued at $3,386,266.80. This trade represents a 36.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Richard Daniell sold 20,003 shares of Teva Pharmaceutical Industries stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $42.80, for a total transaction of $856,128.40. Following the sale, the executive vice president owned 55,755 shares of the company's stock, valued at approximately $2,386,314. This represents a 26.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 715,945 shares of company stock worth $29,061,351 in the last 90 days. Insiders own 0.54% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.